|
RNF141 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.07479580790937E-11 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
3.80889764173276E-11 |
| Normal-vs-Stage2 |
1.164260E-04 |
| Normal-vs-Stage3 |
4.9434999982445E-08 |
| Normal-vs-Stage4 |
3.85700005267609E-09 |
| Stage1-vs-Stage2 |
2.154200E-01 |
| Stage1-vs-Stage3 |
8.765200E-01 |
| Stage1-vs-Stage4 |
1.456790E-01 |
| Stage2-vs-Stage3 |
3.366800E-01 |
| Stage2-vs-Stage4 |
3.716000E-02 |
| Stage3-vs-Stage4 |
1.767170E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
3.61599639120413E-11 |
| Normal-vs-AfricanAmerican |
6.570500E-04 |
| Normal-vs-Asian |
7.35730000256396E-08 |
| Caucasian-vs-AfricanAmerican |
5.281400E-01 |
| Caucasian-vs-Asian |
5.009400E-01 |
| AfricanAmerican-vs-Asian |
3.062200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.04909969600442E-10 |
| Normal-vs-Female |
1.5817003262697E-10 |
| Male-vs-Female |
1.395820E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.96940019847602E-10 |
| Normal-vs-Age(41-60Yrs) |
2.30650054611203E-10 |
| Normal-vs-Age(61-80Yrs) |
3.78650000021352E-07 |
| Normal-vs-Age(81-100Yrs) |
3.871900E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
7.422400E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
4.353600E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
4.988800E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
5.940000E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
5.600800E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
7.338200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
9.996600E-01 |
| Classical-VS-Follicular |
8.408800E-01 |
| Classical-VS-Other |
7.550400E-02 |
| Classical-VS-Normal |
8.50599590762613E-11 |
| Tall-VS-Follicular |
9.066400E-01 |
| Tall-VS-Other |
1.157030E-01 |
| Tall-VS-Normal |
9.83220000000395E-05 |
| Follicular-VS-Other |
1.299960E-01 |
| Follicular-VS-Normal |
2.2352999999864E-06 |
| Other-VS-Normal |
3.037500E-04 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
6.61239996091467E-09 |
| Normal-vs-N1 |
2.45729991910082E-10 |
| N0-vs-N1 |
1.211730E-02 |
|
|
